Piper Sandler Lifts Arista Networks Target 33% to $240 on AI Infrastructure Demand

Piper Sandler raised its price target on ANET to $240 from $181 while reiterating an Overweight rating on Tuesday, marking one of the most aggressive analyst target increases across Wall Street's August 5 research notes and signaling that the artificial intelligence networking boom still has room to run.

Arista Networks has emerged as a primary beneficiary of the hyperscaler arms race in AI data center infrastructure. The firm's cloud networking switches are embedded in the fabric that connects GPU clusters at scale, and Piper Sandler's 33% target hike reflects conviction that Arista's AI-driven revenue trajectory is accelerating rather than plateauing. The stock has been a standout performer in the enterprise networking space, buoyed by consecutive quarters of better-than-expected results tied to large cloud customer deployments. The new $240 price target implies roughly 33% upside from the prior target, placing it among the Street's most bullish calls on the name.

Qualys also drew a dramatic revision from Piper Sandler, which maintained its Neutral rating but boosted its price target 75% to $175 from $100. The cybersecurity firm reported strong second-quarter results on August 4, beating consensus estimates and raising its full-year 2026 outlook, a development that sent shares sharply higher. Qualys has benefited from sustained enterprise spending on vulnerability management and compliance, even as the broader cybersecurity competitive landscape intensifies. The new $175 target reflects Piper Sandler's acknowledgment of improved execution but stops short of an outright bullish call, suggesting the firm sees limited valuation upside from current levels despite the operational momentum.

In healthcare, PROCEPT BioRobotics saw Piper Sandler slash its price target to $25 from $35, a 29% cut, while keeping an Overweight rating. The surgical robotics company posted a second-quarter revenue beat on August 5, but shares declined in the aftermath as investors focused on forward guidance and margin trajectory. PROCEPT's AquaBeam robotic system for benign prostatic hyperplasia continues to gain urological adoption, but the pace of hospital capital equipment purchasing has been uneven. Piper Sandler's reduced target likely reflects tempered near-term revenue assumptions and a more conservative multiple framework, even as the firm maintains its long-term bullish thesis on the company's disruptive technology.

Booking Holdings received two target increases on the same day. Piper Sandler reiterated a Neutral rating and lifted its target to $215 from $195, citing resilient global travel demand, while B. Riley Securities maintained a Buy rating and raised its target to $274 from $264. The divergence in ratings between the two firms underscores a split in how analysts view Booking's valuation at current levels. Piper Sandler's Neutral stance suggests the stock is fairly priced for the travel recovery already priced in, while B. Riley's Buy call implies conviction that Booking's alternative accommodations push and connected-trip strategy will drive earnings above consensus. The travel giant has consistently outperformed expectations in 2026, with cross-border bookings and experience reservations offsetting any softening in domestic leisure.Paylocity Holding rounded out the day's notable moves as Cantor Fitzgerald reaffirmed an Overweight rating and raised its price target to $165 from $140, an 18% increase. The HR and payroll software provider has been expanding its AI capabilities, including the acquisition of leave management platform Aidora in July. Cantor Fitzgerald's bullish revision signals confidence that Paylocity's product bundling strategy and mid-market penetration can sustain above-industry revenue growth. The firm's target suggests roughly 18% upside from the prior target, aligning with the thesis that HR tech spending remains resilient even as enterprises scrutinize software budgets.Trading Opportunities: Investors should consider Arista Networks as a core AI infrastructure holding with a 6-to-12-month horizon. The 33% target increase from Piper Sandler suggests the Street is still calibrating the size of the AI networking opportunity, and any pullback toward the $180 level offers an attractive entry. For Qualys, the 75% target hike after strong earnings creates a momentum trade in the 1-to-3-month window, but the Neutral rating is a warning flag — traders should take partial profits on strength and use a trailing stop. PROCEPT BioRobotics presents a contrarian opportunity: the 29% target cut and post-earnings selloff may be overdone if hospital capital spending recovers in the second half, making a 3-to-6-month mean-reversion play viable with a stop at $20. Booking Holdings offers a pair-trade setup: the Piper Sandler Neutral versus B. Riley Buy divergence creates a catalyst-rich environment around the next earnings report; a straddle strategy ahead of Q3 results could capture the resolution of this analyst disagreement. Paylocity's 18% target hike from Cantor Fitzgerald supports a steady accumulation strategy over 6 months, particularly if the Aidora acquisition begins to contribute to revenue in the next two quarters.

Taken together, Tuesday's analyst actions paint a picture of a market in which conviction is growing on AI-exposed names but tempering on high-multiple growth stories where execution risk is rising. The aggressive target increases for Arista Networks and Qualys reflect real revenue acceleration tied to structural technology trends, while the cut on PROCEPT BioRobotics despite a revenue beat suggests patience is wearing thin on companies that cannot convert top-line growth into sustained margin expansion. The travel sector remains bifurcated between bulls pricing in a multi-year recovery and neutrals arguing the easy money has been made. For investors, the signal is clear: own the names where analysts are racing to raise targets, not just the ones where they are defending existing ratings.